Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)‘s stock had its “buy” rating reiterated by investment analysts at Roth Capital in a research note issued to investors on Tuesday. They currently have a $520.00 price target on the biopharmaceutical company’s stock. Roth Capital’s price target would indicate a potential upside of 30.92% from the stock’s current price.
REGN has been the topic of a number of other research reports. Cowen and Company reissued a “hold” rating and issued a $430.00 target price on shares of Regeneron Pharmaceuticals in a report on Friday, August 5th. Wells Fargo & Co. reaffirmed a “hold” rating on shares of Regeneron Pharmaceuticals in a report on Wednesday, June 8th. Citigroup Inc. reaffirmed a “buy” rating and set a $470.00 price objective on shares of Regeneron Pharmaceuticals in a report on Thursday, June 23rd. Vetr lowered Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating and set a $422.08 price objective on the stock. in a report on Wednesday, July 27th. Finally, Canaccord Genuity reaffirmed a “hold” rating and set a $450.00 price objective on shares of Regeneron Pharmaceuticals in a report on Friday, June 17th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $480.09.
Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded down 1.40% during mid-day trading on Tuesday, hitting $397.20. The company’s stock had a trading volume of 558,306 shares. The company has a market cap of $41.56 billion, a PE ratio of 61.97 and a beta of 1.31. The stock has a 50-day moving average of $403.67 and a 200-day moving average of $391.72. Regeneron Pharmaceuticals has a 12-month low of $329.09 and a 12-month high of $592.59.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, August 4th. The biopharmaceutical company reported $2.82 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.65 by $0.17. The business had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.24 billion. Regeneron Pharmaceuticals had a return on equity of 23.77% and a net margin of 15.65%. The company’s revenue for the quarter was up 21.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.89 earnings per share. On average, equities research analysts forecast that Regeneron Pharmaceuticals will post $11.00 EPS for the current year.
In other news, Director Joseph L. Goldstein sold 2,125 shares of the stock in a transaction dated Friday, July 29th. The stock was sold at an average price of $425.00, for a total value of $903,125.00. Following the completion of the sale, the director now owns 15,125 shares in the company, valued at $6,428,125. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 10.40% of the stock is owned by insiders.
Large investors have recently bought and sold shares of the stock. Evercore Wealth Management LLC raised its stake in Regeneron Pharmaceuticals by 6.1% in the second quarter. Evercore Wealth Management LLC now owns 2,652 shares of the biopharmaceutical company’s stock worth $926,000 after buying an additional 152 shares during the period. Macquarie Group Ltd. raised its stake in Regeneron Pharmaceuticals by 7.7% in the second quarter. Macquarie Group Ltd. now owns 35,214 shares of the biopharmaceutical company’s stock worth $12,298,000 after buying an additional 2,514 shares during the period. Kentucky Retirement Systems Insurance Trust Fund bought a new stake in Regeneron Pharmaceuticals during the second quarter worth about $1,100,000. Kentucky Retirement Systems bought a new stake in Regeneron Pharmaceuticals during the second quarter worth about $2,316,000. Finally, Mason Street Advisors LLC bought a new stake in Regeneron Pharmaceuticals during the second quarter worth about $3,669,000. Institutional investors and hedge funds own 68.16% of the company’s stock.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.